How should ACE inhibitors be used in patients with systemic sclerosis (scleroderma), particularly for renal involvement or scleroderma renal crisis?

ACE Inhibitors in Scleroderma

ACE inhibitors should be started immediately at high doses when scleroderma renal crisis (SRC) is diagnosed and continued long-term, but they should NOT be used prophylactically to prevent SRC in patients without active renal crisis. 1

Treatment of Active Scleroderma Renal Crisis

The evidence is unequivocal despite the absence of randomized controlled trials: immediate initiation of ACE inhibitors is life-saving in SRC. The 2017 and 2025 EULAR guidelines provide the strongest recommendation framework 1, 2:

Survival Impact

• With ACE inhibitors: 76% survival at 1 year, 66% at 5 years
• Without ACE inhibitors: 15% survival at 1 year, 10% at 5 years
• The mortality difference remains significant even after adjusting for age and blood pressure (p=0.001) 1

Specific Treatment Approach

Immediate management when SRC is diagnosed:

• Start ACE inhibitors immediately at diagnosis—do not delay 2
• Use high doses and escalate aggressively to control blood pressure
• Captopril and enalapril have the most published evidence 1
• Continue ACE inhibitors long-term indefinitely as long as there is any potential for kidney function improvement 1
• Renal function recovery can occur up to 3 years after crisis, most commonly within 12-18 months 3

Critical caveat: Even patients requiring dialysis should continue ACE inhibitors lifelong, as approximately 50% may eventually discontinue dialysis 3, 4

Prophylactic Use: DO NOT USE

This is a critical pitfall to avoid. The evidence explicitly contradicts prophylactic ACE inhibitor use:

• Published evidence does not support preventive use of ACE inhibitors to decrease risk or improve outcomes of SRC 1, 2
• A 2022 meta-analysis demonstrated that using ACE inhibitors prior to SRC onset was associated with:
  • Higher incidence of SRC (RR 2.05,95% CI 1.08-3.91, p=0.03)
  • Poorer prognosis (RR 1.46,95% CI 1.20-1.78, p<0.01) 5

The mechanism appears paradoxical but important: prophylactic ACE inhibitors may mask early hypertension that signals impending SRC, delaying diagnosis and treatment 5, 6.

Monitoring Strategy Instead of Prophylaxis

For high-risk patients (diffuse cutaneous SSc, early disease, high skin scores, anti-RNA polymerase III antibodies):

• Monitor blood pressure regularly—this is the surveillance strategy, not prophylactic ACEi 1
• Especially critical: Patients on glucocorticoids (≥15 mg/day prednisone) have 4.4-fold increased SRC risk and require careful blood pressure and renal function monitoring 1
• Avoid high-dose steroids (≥30 mg/day) when possible, as these are associated with normotensive SRC which has worse prognosis 1

Clinical Algorithm

When to start ACE inhibitors:

1. SRC diagnosed (acute severe hypertension + acute kidney injury) → Start immediately at high doses
2. No SRC but SSc present → Do NOT start prophylactically; monitor blood pressure instead
3. On dialysis after SRC → Continue ACE inhibitors indefinitely
4. Recovering from SRC → Continue long-term (up to 3 years or longer if improvement continues)

When to avoid/withhold temporarily:

• Volume depletion states
• Concurrent nephrotoxic drug use
• Severe hypotension
• Bilateral renal artery stenosis (though rare in SSc)

The strength of this recommendation comes from consistent observational data across multiple cohorts totaling over 400 patients, showing dramatic survival differences that make randomized trials ethically impossible 1. The 2025 EULAR update maintains this as a core recommendation with 84% expert agreement 2.